| Genomic deletion of DLC-1 was observed in 40% of breast tumors, whereas reduced levels of DLC-1 mRNA were seen in 70% of breast, 70% of colon, 50% of prostate tumor cell lines.DLC-1 gene plays a role in breast cancer by acting as a tumor suppressor gene | colorectal,breast,prostate, |
| DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma. | liver, |
| Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. | gastric, |
| DLC-1 plays a role in non-small cell lung carcinoma by acting as a bona fide new tumor suppressor gene. | lung, |
| Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. | lung, |
| Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas. | lymphoma, |
| The results suggest that DLC1 may function as a tumor suppressor gene in meningiomas. Furthermore, DLC1 promoter methylation does not appear to be responsible for the decreased DLC1 expression in these tumors. | meningiomas, |
| Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. | liver,prostate, |
| Phosphorylation of deleted in liver cancer 1 (DLC1) and DLC2 by Akt at the conserved residue points to a common regulatory mechanism of the DLC tumor suppressor family. | liver, |
| DLC-1 may play an important role in lymphoma by acting as a bona fide new tumor suppressor gene. | lymphoma, |
| Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). | liver, |
| The Deleted in Liver Cancer 1 (Dlc1) tumor suppressor is haploinsufficient for mammary gland development and epithelial cell polarity | liver, |
| DLC-1 acts as a tumor suppressor gene in HCC by regulating the expression of RhoA/ROCK2/ moesin. | liver, |
| Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications | liver, |
| Tumor suppressor genes deleted in liver cancer 1 (DLC1), F-box/WD-repeat-containing protein 7 (FBXW7), and cadherin-6 (CDH6) were identified as presumed targets in Cholangiocarcinoma (CC).Inverse correlation between promoter methylation and expression suggested miR-129-2 and members of the miR-200 family (miR-200a, miR-200b, and miR-429) as novel tumor suppressors and oncomiRs, respectively, in CC | liver,cholangiocarcinoma, |
| The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma | liver, |
| Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer | breast, |
| DLC1 tumor suppressor regulates CD105 expression on human non-small cell lung carcinoma cells through inhibiting TGFB1 signaling. | lung, |
| Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. | None |
| genomic deletion and promoter methylation primarily account for the altered expression and tumor suppressive inactivation of the DLC-1 gene | None |